Gelatin methacryloyl hydrogel as a potential scaffold for cell transplantation for Huntington’s disease
Brain Communications · 2026-07-01 · 8 (4)
DOI: 10.1093/braincomms/fcag295 ↗At a glance
Journal article in Brain Communications, published online on 2026-07-27. Written by Linh Nguyen and 2 co-authors. Institution: Department of Pharmacology and Clinical Pharmacology, Centre for Brain Research, School of Medical Science, Faculty of Medical and Health Sciences, U…. 29 references. The full text is freely available (open access, CC BY 4.0). Funded by: Royal Society of New Zealand Marsden Fund, Hudson-Nilon Medical Research Foundation.
Abstract (original language)
Cell replacement therapy is a promising strategy for treating Huntington’s disease. Advances in cell reprogramming now allow the generation of clinically relevant cells; however, conventional delivery methods can compromise long-term cell survival and maturation. Hydrogels have emerged as supportive three-dimensional scaffolds that better mimic the in vivo environment. This study examined whether encapsulating human-induced lateral ganglionic eminence precursor cells (hiLGEPs) in gelatin methacryloyl (GelMA) hydrogel enhanced differentiation after transplantation into the striatum of the quinolinic acid lesion rat model of Huntington’s disease. hiLGEPs were delivered either in cell culture medium (n = 5) or in a pre-crosslinked GelMA solution (n = 4) prior to transplantation. GelMA was polymerized in situ using a visible-light optical fibre system, and grafts were assessed 4 weeks later. Transplanted cells survived in all animals. Notably, GelMA-encapsulated hiLGEPs produced significantly more protein gene product 9.5 (PGP9.5+) neurons than those delivered in cell culture medium. Transplanted cells in both groups differentiated into microtubule-associated protein 2 (MAP2+) and GABA+ phenotypes, with no detectable differences in graft volume. These findings provide the first evidence that encapsulating hiLGEPs in GelMA enhances early neuronal differentiation following transplantation, supporting GelMA hydrogel as a promising delivery scaffold for cell replacement therapy in Huntington’s disease.
Subjects
Author keywords
Authors and institutions
- Department of Pharmacology and Clinical Pharmacology, Centre for Brain Research, School of Medical Science, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New Zealand.
ORCID profiles: Amy McCaughey-Chapman
Funding
- Royal Society of New Zealand Marsden Fund
- Hudson-Nilon Medical Research Foundation
Cite
APA
Nguyen, L., McCaughey-Chapman, A., & Connor, B. (2026). Gelatin methacryloyl hydrogel as a potential scaffold for cell transplantation for Huntington’s disease. Brain Communications, 8(4). https://doi.org/10.1093/braincomms/fcag295
Vancouver
Nguyen L, McCaughey-Chapman A, Connor B. Gelatin methacryloyl hydrogel as a potential scaffold for cell transplantation for Huntington’s disease. Brain Communications. 2026;8(4). doi:10.1093/braincomms/fcag295
BibTeX
@article{Nguyen2026,
author = {Nguyen, Linh and McCaughey-Chapman, Amy and Connor, Bronwen},
title = {Gelatin methacryloyl hydrogel as a potential scaffold for cell transplantation for Huntington’s disease},
journal = {Brain Communications},
year = {2026},
volume = {8},
number = {4},
doi = {10.1093/braincomms/fcag295}
}
EUVIMED